Advertisement
UK markets close in 2 hours 42 minutes

  • FTSE 100

    8,125.17
    +46.31 (+0.57%)
     

  • FTSE 250

    19,836.47
    +234.49 (+1.20%)
     

  • AIM

    755.39
    +2.27 (+0.30%)
     

  • GBP/EUR

    1.1668
    +0.0012 (+0.10%)
     

  • GBP/USD

    1.2506
    -0.0005 (-0.04%)
     

  • Bitcoin GBP

    51,458.30
    +511.70 (+1.00%)
     

  • CMC Crypto 200

    1,390.88
    -5.65 (-0.41%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CRUDE OIL

    84.19
    +0.62 (+0.74%)
     

  • GOLD FUTURES

    2,360.40
    +17.90 (+0.76%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,085.19
    +167.91 (+0.94%)
     

  • CAC 40

    8,062.16
    +45.51 (+0.57%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Drugmaker AstraZeneca's earnings fall, hit by patent expiries

Reuters - UK Focus

LONDON, April 29 (Reuters) - AstraZeneca (NYSE: AZN - news) 's underlying earnings fell 12 percent in the first quarter, broadly in line with analyst expectations, hit by drug patent expiries.

Revenue at the British drug company rose 1 percent in dollar terms to $6.12 billion, helped by income from selling rights to some drugs, generating core earnings per share, which exclude certain items, of 95 cents.

Industry analysts had on average forecast quarterly revenue of $5.93 billion and earnings of 94 cents a share, according to Thomson Reuters (Dusseldorf: TOC.DU - news) .

AstraZeneca reiterated on Friday that it expects a low to mid single-digit percentage decline in both revenue and core earnings at constant exchange rates for the full year. (Reporting by Ben Hirschler; Editing by David Goodman)